WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...

做疫苗的人都知道一个心照不宣的事实：传统疫苗开发太慢了。 从病原体分离、抗原鉴定、临床前评价到三期临床，平均要 10 到 15 年，单支疫苗的研发成本估计超过 10 亿美元。HPV 疫苗 Gardasil 从实验室到上市花了 15 年，轮状病毒疫苗 ...

It's a tremendous sign of success for the vaccine, but it's also a personalized vaccine. That means it can't simply be ...

Moderna shares climb 6.8% on myeloma and Ebola vaccine updates, but quarterly results due Nov 6 will test the business behind ...

Moderna said its vaccine to protect against ebola was recommended to advance into a Phase 2/3 trial in Congo. Pending regulatory approval, Moderna's mRNA-1469 vaccine will be tested to prevent ...

Moderna (NasdaqGS:MRNA) faces fresh regulatory questions as prediction markets start trading on FDA timelines for its ...

Moderna shares rose 8.8% to $248.63 after mRNA-1469 advanced toward Phase 2/3 trials in the DRC targeting Bundibugyo ...

Moderna (MRNA) will advance its investigational mRNA-1469 vaccine candidate against Bundibugyo ebolavirus toward a phase 2/3 efficacy study in the Democratic Republic of the Congo ...

Moderna, Inc. (NASDAQ: MRNA) announced that its investigational mRNA vaccine candidate, mRNA-1469, targeting Bundibugyo ebolavirus (BDBV), has been recommended to advance into a Phase 2/3 efficacy ...

Since the start of this year, Moderna (MRNA) has become the hottest stock in the S&P 500, with gains far exceeding 600%.

Moderna has received FDA approval for a new flu vaccine designed for adults ages 50 and older. Learn more about this new ...

Key TakeawaysModerna shares jumped 8% after its myeloma therapy, mRNA-2808, showed four confirmed responses among 11 heavily pretreated patients. The data shows Moderna’s mRNA can get the body to make ...